ArticleGene therapy2006
Astrocytic expression of transgene in the rat brain mediated by baculovirus vectors containing an astrocyte-specific promoter.
Article in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Astrocytic noncanonical WNT5B signaling modulates extracellular matrix remodeling and neuropathology in Huntington's disease.Signal transduction and targeted therapy · 2026Article
- Assembly of Baculovirus Vectors for Multiplexed Prime Editing.Methods in molecular biology (Clifton, N.J.) · 2024Article
- A custom-made AAV1 variant (AAV1-T593K) enables efficient transduction of Japanese quail neurons in vitro and in vivo.Communications biology · 2023Article
- Article
- Reaching for the Stars in the Brain: Polymer-Mediated Gene Delivery to Human Astrocytes.Molecular therapy. Nucleic acids · 2018Article
- Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Review
- Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials.Molecular therapy. Methods & clinical development · 2016Review
- Review
- Gene therapy for the nervous system: challenges and new strategies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Review
- In the rat liver, Adenoviral gene transfer efficiency is comparable to AAV.Gene therapy · 2014Article
- Article
- Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors.Frontiers in cellular neuroscience · 2013Article
- Development of the hybrid Sleeping Beauty: baculovirus vector for sustained gene expression and cancer therapy.Gene therapy · 2012Article
- Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype.Cellular and molecular neurobiology · 2011Article
- Baculovirus vectors for antiangiogenesis-based cancer gene therapy.Cancer gene therapy · 2011Article
- Recent developments in the understanding of astrocyte function in the cerebellum in vivo.Cerebellum (London, England) · 2010Review
- Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Intrathecal injection of naked plasmid DNA provides long-term expression of secreted proteins.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Hybrid baculovirus-adeno-associated virus vectors for prolonged transgene expression in human neural cells.Journal of neurovirology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic gene expression in glial cells has been tested for the treatment of neurological diseases in animal models. Many of such studies used the promoter of the glial fibrillary acidic protein (GFAP) to restrict gene expression to astrocytes. We have investigated in the current study whether it is possible to improve the transcriptional activity of the cellular promoter, while maintaining its cell-type specificity. We constructed an expression cassette containing a hybrid cytomegalovirus (CMV) enhancer/GFAP promoter and placed it into baculovirus vectors, a type of viral vectors capable of transducing astrocytes. In another vector design, we used inverted terminal repeats (ITRs) from adeno-associated virus (AAV) to flank the expression cassette. The recombinant baculoviruses with the hybrid promoter improved gene expression levels over two orders of magnitude in glial cell lines and by 10-fold in the rat brain when compared to the baculoviruses with the GFAP promoter alone. The expression was further improved by ITR flanking, reaching levels higher than that mediated by the baculovirus vectors with the CMV immediate-early enhancer/promoter (CMV promoter). Using these recombinant baculoviruses, we observed extended in vivo transgene expression in the rat brain at 90 days postinjection, by which time the gene expression from baculovirus vectors with the GFAP or CMV promoter had already become undetectable. The astrocyte specificity of the GFAP promoter was preserved in the engineered expression cassette with the CMV enhancer and the AAV ITRs, as demonstrated by immunohistological analysis of brain samples and an axonal retrograde transport assay. Taken together, our findings suggest that these baculovirus vectors may serve as useful tools for astrocyte-specific gene expression in the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.